Nello Mainolfi's most recent trade in Kymera Therapeutics Inc was a trade of 80,000 Common Stock done at an average price of $2.1 . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 01 Jul 2026 | 80,000 | 746,568 | - | 2.1 | 166,400 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 80,000 | 135,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 115.69 per share. | 01 Jul 2026 | 44,050 | 669,904 | - | 115.7 | 5,096,070 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 114.96 per share. | 01 Jul 2026 | 24,105 | 713,954 | - | 115.0 | 2,771,002 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 113.98 per share. | 01 Jul 2026 | 6,626 | 738,059 | - | 114.0 | 755,204 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 116.56 per share. | 01 Jul 2026 | 3,336 | 666,568 | - | 116.6 | 388,841 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 112.80 per share. | 01 Jul 2026 | 1,883 | 744,685 | - | 112.8 | 212,411 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 29 Apr 2026 | 30,000 | 696,195 | - | 2.1 | 62,400 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2026 | 30,000 | 215,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 80.74 per share. | 29 Apr 2026 | 17,005 | 679,190 | - | 80.7 | 1,372,984 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 81.70 per share. | 29 Apr 2026 | 12,059 | 667,131 | - | 81.7 | 985,220 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.45 per share. | 29 Apr 2026 | 936 | 666,195 | - | 82.4 | 77,173 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 215,000 | 215,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 25 Feb 2026 | 30,000 | 696,195 | - | 2.1 | 62,400 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2026 | 30,000 | 245,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 89.78 per share. | 25 Feb 2026 | 19,764 | 676,431 | - | 89.8 | 1,774,412 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 90.39 per share. | 25 Feb 2026 | 5,434 | 670,997 | - | 90.4 | 491,179 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 91.76 per share. | 25 Feb 2026 | 3,293 | 667,704 | - | 91.8 | 302,166 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 92.81 per share. | 25 Feb 2026 | 1,501 | 666,203 | - | 92.8 | 139,308 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 93.50 per share. | 25 Feb 2026 | 8 | 666,195 | - | 93.5 | 748 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.07 per share. | 05 Jan 2026 | 3,118 | 666,195 | - | 32.1 | 99,994 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 3,118 | 446,882 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 31 Dec 2025 | 30,000 | 693,077 | - | 2.1 | 62,400 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 30,000 | 275,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.95 per share. | 31 Dec 2025 | 23,986 | 669,091 | - | 78.0 | 1,869,728 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.52 per share. | 31 Dec 2025 | 6,014 | 663,077 | - | 78.5 | 472,211 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 2,595 | 272,505 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.53 per share. | 17 Dec 2025 | 2,595 | 663,077 | - | 38.5 | 99,985 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 89.17 per share. | 08 Dec 2025 | 100,000 | 660,482 | - | 89.2 | 8,917,000 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 08 Dec 2025 | 100,000 | 760,482 | - | 2.1 | 208,000 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 100,000 | 305,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 29 Oct 2025 | 30,000 | 690,482 | - | 2.1 | 62,400 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2025 | 30,000 | 405,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 61.02 per share. | 29 Oct 2025 | 24,511 | 664,109 | - | 61.0 | 1,495,627 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 61.46 per share. | 29 Oct 2025 | 3,627 | 660,482 | - | 61.5 | 222,907 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 59.72 per share. | 29 Oct 2025 | 1,862 | 688,620 | - | 59.7 | 111,203 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2025 | 30,000 | 435,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 16 Sep 2025 | 30,000 | 660,482 | - | 49 | 1,470,000 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 16 Sep 2025 | 30,000 | 690,482 | - | 2.1 | 62,400 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Jun 2025 | 30,000 | 690,482 | - | 2.1 | 62,400 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 30,000 | 465,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 03 Jun 2025 | 30,000 | 660,482 | - | 49 | 1,470,000 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 365,000 | 365,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 10 Jan 2025 | 10,000 | 659,959 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2025 | 10,000 | 495,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 18,773 | 288,456 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.33 per share. | 01 Jul 2024 | 18,773 | 649,959 | - | 5.3 | 100,060 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 18 Jun 2024 | 14,413 | 631,186 | - | 2.1 | 29,979 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 14,413 | 505,559 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 530,000 | 530,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 9,000 | 519,972 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 02 Jan 2024 | 9,000 | 615,570 | - | 2.1 | 18,720 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 12,000 | 2,368 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 08 Aug 2023 | 12,000 | 586,570 | - | 2.1 | 24,960 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2022 | 10,000 | 18,725 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 08 Dec 2022 | 10,000 | 573,700 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 32,056 | 14,368 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 17 Oct 2022 | 32,056 | 534,255 | - | 2.1 | 66,676 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 17 Oct 2022 | 27,676 | 561,931 | - | 2.1 | 57,566 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 27,676 | 546,604 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 May 2022 | 20,000 | 502,199 | - | 2.1 | 41,600 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 20,000 | 46,424 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 275,100 | 275,100 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 10,000 | 66,424 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 14 Jan 2022 | 10,000 | 482,199 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 10 Jan 2022 | 22,465 | 494,664 | - | 2.1 | 46,727 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2022 | 22,465 | 599,815 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 10 Jan 2022 | 16,923 | 489,122 | - | 2.1 | 35,200 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2022 | 16,923 | 582,892 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 53.35 per share. | 10 Jan 2022 | 10,673 | 476,506 | - | 53.3 | 569,379 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 53.68 per share. | 10 Jan 2022 | 9,932 | 479,190 | - | 53.7 | 533,109 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 10 Jan 2022 | 8,612 | 480,811 | - | 2.1 | 17,913 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2022 | 8,612 | 574,280 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.46 per share. | 10 Jan 2022 | 7,485 | 487,179 | - | 52.5 | 392,644 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 54.42 per share. | 10 Jan 2022 | 6,644 | 472,546 | - | 54.4 | 361,582 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 54.40 per share. | 10 Jan 2022 | 4,201 | 472,305 | - | 54.4 | 228,545 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.02 per share. | 10 Jan 2022 | 4,022 | 474,063 | - | 52.0 | 209,210 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 51.31 per share. | 10 Jan 2022 | 2,726 | 478,085 | - | 51.3 | 139,877 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 53.27 per share. | 10 Jan 2022 | 1,623 | 472,440 | - | 53.3 | 86,457 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.05 per share. | 10 Jan 2022 | 347 | 472,199 | - | 55.1 | 19,103 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 53.97 per share. | 10 Jan 2022 | 241 | 472,199 | - | 54.0 | 13,007 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 54.99 per share. | 10 Jan 2022 | 106 | 472,199 | - | 55.0 | 5,829 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 16 Dec 2021 | 8,000 | 472,199 | - | 2.1 | 16,640 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2021 | 8,000 | 76,424 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2021 | 41,544 | 35,181 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 08 Oct 2021 | 41,544 | 505,743 | - | 2.1 | 86,412 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.56 per share. | 08 Oct 2021 | 21,236 | 484,507 | - | 55.6 | 1,179,868 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 56.82 per share. | 08 Oct 2021 | 9,369 | 475,138 | - | 56.8 | 532,391 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 59.28 per share. | 08 Oct 2021 | 7,920 | 465,140 | - | 59.3 | 469,463 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2021 | 6,456 | 28,725 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 08 Oct 2021 | 6,456 | 470,655 | - | 2.1 | 13,428 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 53.58 per share. | 08 Oct 2021 | 5,712 | 464,943 | - | 53.6 | 306,044 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 57.29 per share. | 08 Oct 2021 | 2,078 | 473,060 | - | 57.3 | 119,046 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 54.50 per share. | 08 Oct 2021 | 744 | 464,199 | - | 54.5 | 40,546 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.32 per share. | 08 Oct 2021 | 670 | 464,470 | - | 60.3 | 40,412 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 61.87 per share. | 08 Oct 2021 | 271 | 464,199 | - | 61.9 | 16,767 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 12,000 | 84,424 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 19 Aug 2021 | 12,000 | 464,199 | - | 2.1 | 24,960 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.07 per share. | 03 Aug 2021 | 5,669 | 452,199 | - | 60.1 | 340,533 | Common Stock |
| Kymera Therapeutics Inc | Nello Mainolfi | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 5,669 | 77,762 | - | - | Stock Option (Right to Buy) |